『Skin and Joints Podcast』のカバーアート

Skin and Joints Podcast

Skin and Joints Podcast

著者： Mimi Tran Aaron Sihota Danny Mansour Ashley Yip Julia Tan Touraj Khosravi Anastasiya Muntyanu
無料で聴く

このコンテンツについて

 A national multidisciplinary masterclass exploring inflammatory skin and joint related conditions led by healthcare experts from across Canada and the US.2024 Skin and Joints Podcast 生物科学 科学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • (PART 2) Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025

    (PART 2) Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025
    2025/10/08
    Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025Guests: Dr. Chloe Ward & Dr. Natalie CunninghamLocation: 📍 EADV 2025, Paris 🇫🇷From café chatter to late-breaker abstracts, this fresh field report stitches together breaking new data and what matters for acne care today. Our two Canadian derm Faculty dynamos, Dr. Chloe Ward and Dr. Natalie Cunningham, join us live from EADV 2025 to decode acne in the TikTok age. We swap “Dr. Google” for real talk on psychosocial fallout (filters, FOMO, and 4 a.m. routines), sanity-check the diet myths, and map where AI actually helps in assessment—think consistent severity tracking and smarter primary-care triage—without replacing clinical eyes (especially in richer skin tones).Drs. Ward and Cunningham unpack multimodal regimens patients can actually tolerate, topical androgen-receptor blockade at the sebaceous unit, and smarter maintenance so scars don’t steal the show. We dig into pigment beyond classic PIH (hello, primary melanogenesis), when energy devices earn a seat (including a 1726-nm sebaceous-targeting laser), why most at-home red light is a detour, and the rare moments biologics enter the chat for overlap/refractory cases. Throughout: practical pearls and fresh evidence Learning ObjectivesAfter this episode, participants will be able to:🧠 Assess psychosocial burden in acne (sleep 💤, stress 😰, social media behaviors 📱) and integrate into severity and treatment decisions 🩺.🥗 Debunk prevalent myths (“diet cures acne” ❌) with balanced, evidence-based counseling 📖 that acknowledges diet/stress/hormones as contributors, not sole causes ⚖️.🧴 Design patient-centered, multimodal regimens that optimize efficacy ✅ and tolerability 🤝—leveraging combination therapy 🔗.🧬 Explain mechanisms (incl. topical androgen-receptor blockade at the sebaceous gland) and position them in stepwise care from induction 🚀 to maintenance 🔁.🎨 Differentiate pigment pathways (PIH vs. emerging primary melanogenesis) and tailor strategies for all skin tones 🌈 with rigorous photoprotection 🧢🕶️.🤖 Use AI judiciously for documentation 📝 and triage 🏥; recognize limitations in diverse skin tones 🌍 and keep the patient’s lived experience central ❤️.🛡️ Prevent scars proactively by identifying scar-risk patients early ⏱️ and escalating appropriately (e.g., isotretinoin candidacy) 🎯.🔦 Outline the role of energy-based devices (including the 1726-nm sebaceous-targeting laser) in reducing inflammation 🔥, erythema 🌺, and remodeling 🧱—and why most at-home red-light devices fall short 🚫🔴.🧬 Spot the edge cases where biologics or overlap-syndrome thinking may be appropriate 🧩, and outline key research gaps to watch 🔭 (hormonal pathways, AI validation, long-term maintenance). Perfect forDermatologists, primary-care clinicians, pharmacists, nurses, and any HCP who fields “I saw this on TikTok…” and wants practical, patient-first to translate Paris-level science into Monday-morning care. ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NSDr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact scientific journals and is the research director at Maritime Dermatology. ABOUT Dr. Chloé Ward, MD, FRCP(C), DABD OTTAWA, ONChloé Ward, MD, FRCP(C), DABD is a board-certified dermatologist working alongside our team of plastic surgeons at The Ottawa Clinic. She specializes in cutaneous laser surgery and helps patients with a wide range of cosmetic and medical skin care needs. ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NSDr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact ...
    続きを読む 一部表示
    23 分
  • Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025

    Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025
    2025/10/06
    Acne in Paris: Croissants, Comedones & Cutting-Edge Care at EADV 2025Guests: Dr. Chloe Ward & Dr. Natalie CunninghamLocation: 📍 EADV 2025, Paris 🇫🇷From café chatter to late-breaker abstracts, this fresh field report stitches together breaking new data and what matters for acne care today. Our two Canadian derm Faculty dynamos, Dr. Chloe Ward and Dr. Natalie Cunningham, join us live from EADV 2025 to decode acne in the TikTok age. We swap “Dr. Google” for real talk on psychosocial fallout (filters, FOMO, and 4 a.m. routines), sanity-check the diet myths, and map where AI actually helps in assessment—think consistent severity tracking and smarter primary-care triage—without replacing clinical eyes (especially in richer skin tones).Drs. Ward and Cunningham unpack multimodal regimens patients can actually tolerate, topical androgen-receptor blockade at the sebaceous unit, and smarter maintenance so scars don’t steal the show. We dig into pigment beyond classic PIH (hello, primary melanogenesis), when energy devices earn a seat (including a 1726-nm sebaceous-targeting laser), why most at-home red light is a detour, and the rare moments biologics enter the chat for overlap/refractory cases. Throughout: practical pearls and fresh evidence Learning ObjectivesAfter this episode, participants will be able to:🧠 Assess psychosocial burden in acne (sleep 💤, stress 😰, social media behaviors 📱) and integrate into severity and treatment decisions 🩺.🥗 Debunk prevalent myths (“diet cures acne” ❌) with balanced, evidence-based counseling 📖 that acknowledges diet/stress/hormones as contributors, not sole causes ⚖️.🧴 Design patient-centered, multimodal regimens that optimize efficacy ✅ and tolerability 🤝—leveraging combination therapy 🔗.🧬 Explain mechanisms (incl. topical androgen-receptor blockade at the sebaceous gland) and position them in stepwise care from induction 🚀 to maintenance 🔁.🎨 Differentiate pigment pathways (PIH vs. emerging primary melanogenesis) and tailor strategies for all skin tones 🌈 with rigorous photoprotection 🧢🕶️.🤖 Use AI judiciously for documentation 📝 and triage 🏥; recognize limitations in diverse skin tones 🌍 and keep the patient’s lived experience central ❤️.🛡️ Prevent scars proactively by identifying scar-risk patients early ⏱️ and escalating appropriately (e.g., isotretinoin candidacy) 🎯.🔦 Outline the role of energy-based devices (including the 1726-nm sebaceous-targeting laser) in reducing inflammation 🔥, erythema 🌺, and remodeling 🧱—and why most at-home red-light devices fall short 🚫🔴.🧬 Spot the edge cases where biologics or overlap-syndrome thinking may be appropriate 🧩, and outline key research gaps to watch 🔭 (hormonal pathways, AI validation, long-term maintenance). Perfect forDermatologists, primary-care clinicians, pharmacists, nurses, and any HCP who fields “I saw this on TikTok…” and wants practical, patient-first to translate Paris-level science into Monday-morning care. ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NSDr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact scientific journals and is the research director at Maritime Dermatology. ABOUT Dr. Chloé Ward, MD, FRCP(C), DABD OTTAWA, ONChloé Ward, MD, FRCP(C), DABD is a board-certified dermatologist working alongside our team of plastic surgeons at The Ottawa Clinic. She specializes in cutaneous laser surgery and helps patients with a wide range of cosmetic and medical skin care needs. ABOUT Dr Natalie Cunningham, MD FRCPC HALIFAX, NSDr. Cunningham is a co-founder of Maritime Dermatology and was born and raised in Halifax, Nova Scotia. Her roots are in Yarmouth, Nova Scotia and Vienna, Austria. She completed a Bachelor of Science in Neuroscience, Medical School and Dermatology Residency, serving as chief resident, at Dalhousie University. She passed her Royal College examination in 2017. She has been active in medical education and is assistant professor in the department of medicine at Dalhousie medical school. She sees patients of all ages and has a pediatric dermatology clinic at the IWK where she also supervises medical students and residents. She is active in research and has publications in high impact ...
    続きを読む 一部表示
    20 分
  • Melinda Knows Best: EADV 2025 Chronic Hand Eczema Paris Pop-Up with Dr.Melinda Gooderham

    Melinda Knows Best: EADV 2025 Chronic Hand Eczema Paris Pop-Up with Dr.Melinda Gooderham
    2025/10/02
    Paris Pop-Up: Hands Down the Most Fun You’ll Have Learning About Chronic Hand Eczema Late Breaker EditionChronic Hand Eczema in Focus: DELTA-Teen efficacy & pooled safety of topical pan-JAK Episode Tasting Menu 🍽️:Jet-lag ✈️, steak-frites , and NEW science : we unpack fresh adolescent data for a topical pan-JAK cream in chronic hand eczema (CHE) and a pooled safety package that’s so uneventful it’s…beautiful 😌. (Melinda’s words: “Boring is good.”)Fresh from EADV Paris 🗼🇫🇷, the team breaks down two late-breaking updates on CHE:DELTA-Teen — a randomized (3:1) 16-week trial of a topical pan-JAK inhibitor (delgocitinib cream) in adolescents (12–17) with moderate–severe CHE. 📊Pooled safety analysis across five trials (Phase 2b/3; 16-week regular use + up to 52-week as-needed). 🛡️📈What’s on the tasting menu :• EADV in Paris — highlights with a dash of Melinda’s Paris story 🥐📸• Current adolescent CHE care — steroid limits & non-steroidal gaps • DELTA-Teen unpacked — design, endpoints, results, onset, adherence impact • Safety deep-dive — pooled 5-trial analysis, 52-week PRN, counseling talking points • Practice pearls — payer metrics (IGA-CHE), cross-setting messaging, fast-tracking from primary care • Wrap — off-label nuance, what to tell parents/teens, what to watch for nextWe dive into where a non-steroidal topical JAK can fit for adolescents—an area with gaps given steroid hesitancy and tolerability issues with other non-steroidals 🧩.Plus, a practical workflow map 🗺️: primary care triage → dermatology fast-track → pharmacy counseling (steroid fears, adherence benefits from rapid itch relief) → documentation (expect IGA-CHE to be required by payers). Importantly, efficacy signals span CHE subtypes (atopic, irritant, allergic) ✅—supporting broad real-world relevance 🌍. Learning objectives 🎯:Describe the DELTA-Teen trial design for adolescent CHE, including primary (IGA-CHE TS) and key secondary endpoints (HECSI-90, HESD itch/pain).Interpret week-16 efficacy results and differentiate early patient-reported benefits from statistical-significance timing (e.g., week-12 separation)—and weave this into adherence counseling ⏳.Summarize pooled safety across five trials (16-week regular use + up to 52-week PRN): common AEs, no increased AE rates vs vehicle, and implications of minimal systemic absorption & no boxed warning for topical delgocitinib 🛡️📉.Identify gaps in adolescent CHE management (steroid limitations, tolerability of other non-steroidals) and position topical pan-JAK inhibitors appropriately—acknowledging off-label use where applicable 🧭.Apply a care-pathway playbook (primary care → dermatology → pharmacy counseling → payer documentation) and document outcomes likely required for access (e.g., IGA-CHE scoring) across CHE subtypes 📋✅. Practical pearls (AKA Clinic Cheat Codes) :• Expect early itch relief that can boost adherence; set expectations about week-12 statistical separation ⏱️🙌.• Use IGA-CHE in documentation; keep HECSI-90/HESD in mind for research/quality initiatives 📝🔍.• Safety talking points: AEs comparable to vehicle; long-term PRN data up to 52 weeks; discuss the no boxed warning context vs class concerns 🛡️🗣️.• Reinforce steroid-sparing options to address teen/parent anxieties about skin thinning 🧴.• Subtype-agnostic efficacy supports practical use while you sort mixed etiologies 🧪🔄.—Notes ⚠️🗒️: Adolescent use discussed here reflects off-label prescribing in many regions pending any label extension. Always consult local product labeling and guidance.#SkinAndJointsPodcast #ChronicHandEczema #CHE #EADV2025 #Paris #Dermatology #DELTATeen #Delgocitinib #JAKInhibitor #TopicalJAK #AdolescentDerm #PediatricDerm #ItchRelief #SteroidSparing #ClinicalTrials #RealWorldEvidence #IGACHE #HECSI90 #HESD #PracticePearls #DermPharmacy #MedEd #HCPs #EvidenceBasedDermSUPPORTED BY AN IME GRANT FROM LEO PHARMA ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)Toronto, ONMelinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.📻www.skinandjoints.ca✉️info@skinandjoints.ca 📻www.skinandjoints.ca✉️info@skinandjoints.ca Hosted ...
    続きを読む 一部表示
    25 分
まだレビューはありません